How does Enspryng treat neuromyelitis optica?

What is neuromyelitis optica?

Neuromyelitis optica (NMO) is a rare and chronic autoimmune disease that affects the central nervous system. It's characterized by inflammation in the optic nerves and spinal cord, leading to vision loss and other neurologic symptoms.

What is Enspryng, and how does it treat NMO?

Enspryng (satralizumab-mwge) is a humanized monoclonal antibody that targets aquaporin-4 (AQP4), a protein found on the surface of astrocytes, a type of immune cell in the central nervous system. By blocking AQP4, Enspryng reduces the binding of antibodies to this protein, which is a key factor in the development of NMO [1].

Enspryng is designed to prevent or slow down the disease's progression by reducing the inflammation and damage caused by the body's immune response. The treatment has been shown to be effective in reducing the frequency of relapses and slowing down the progression of NMO-related disability [2].

Clinical trials and approvals

Enspryng has undergone clinical trials in patients with NMO, demonstrating its safety and efficacy. It was approved by the US FDA in March 2020 for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a condition characterized by recurring episodes of NMO.

Comparison to other treatments

Enspryng is the first monoclonal antibody approved for the treatment of NMOSD. While other treatments, such as glucocorticoids and azathioprine, are available, Enspryng offers a targeted approach that may reduce the risk of side effects and improve treatment outcomes for patients with NMO.

Side effects and patient concerns

Common side effects of Enspryng include injection site reactions, upper respiratory infections, and urinary tract infections. Patients should discuss the potential risks and benefits of treatment with their healthcare provider.

Pricing and availability

The cost of Enspryng can be high, and insurance coverage may vary. Patients should consult with their healthcare provider and insurance provider to determine the out-of-pocket costs.

Sources:
[1] DrugPatentWatch.com: Enspryng (satralizumab-mwge)
[2] ClinicalTrials.gov: Study of Satralizumab-Mwge in Participants with Neuromyelitis Optica Spectrum Disorder (EN Hammock)

External Source:
https://www.drugpatentwatch.com/drug/Enspryng